Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Lipitor

- PMLiVE

AbbVie’s long-term Rinvoq data shows continued repigmentation in non-segmental vitiligo

The use of Rinvoq in non-segmental vitiligo is under regulatory review by the US FDA

- PMLiVE

Pfizer’s Litfulo significantly improved repigmentation in nonsegmental vitiligo

NSV is a chronic autoimmune disease where the immune system attacks melanin-producing cells, leading to a loss of pigment

- PMLiVE

Novartis’ Cosentyx gets positive CHMP opinion for polymyalgia rheumatica

If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica

- PMLiVE

Novartis announces trial results for remibrutinib in relapsing multiple sclerosis

MS affects nearly three million people worldwide and has three main types

- PMLiVE

Pfizer and Valneva’s application for Lyme disease vaccine candidate validated by EMA

There are currently no approved human vaccines for Lyme disease

- PMLiVE

Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer

More than 186,000 men are diagnosed each year with mHSPC globally

- PMLiVE

AbbVie’s Rinvoq approved by European Commission for non-segmental vitiligo

Rinvoq is the first and only systemic medication approved in the EU for NSV

- PMLiVE

Pfizer announces phase 3 results for nonsegmental vitiligo treatment

Litfulo delivered significant, clinically meaningful improvements for both face and body

- PMLiVE

Pfizer’s Talzenna plus Xtandi gets FDA Priority Review for metastatic prostate cancer

The phase 3 trial showed greater than 50% improvement in radiographic progression-free survival

- PMLiVE

Novartis to acquire Myricx Bio in deal worth $1.5bn

Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates

- PMLiVE

Pfizer announces phase 3 results for potential non-small cell lung cancer treatment

Patients who had received only one prior line of systemic therapy showed a stronger trend for overall survival and progression-free survival

- PMLiVE

Gilead’s Trodelvy approved by EC as first-line treatment for metastatic triple-negative breast cancer

TNBC is the most aggressive type of breast cancer and has historically been difficult to treat

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links